Ventures L.P. 5Am Sells 114,756 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Ventures L.P. 5Am sold 114,756 shares of the business’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $6.93, for a total transaction of $795,259.08. Following the completion of the transaction, the insider owned 2,848,310 shares in the company, valued at $19,738,788.30. The trade was a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Entrada Therapeutics Stock Up 6.9%

Shares of Entrada Therapeutics stock traded up $0.47 during mid-day trading on Monday, hitting $7.26. The stock had a trading volume of 500,498 shares, compared to its average volume of 329,656. The firm has a 50-day moving average of $6.83 and a two-hundred day moving average of $9.84. The firm has a market cap of $281.84 million, a P/E ratio of -1.82 and a beta of -0.26. Entrada Therapeutics, Inc. has a 12-month low of $4.93 and a 12-month high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.95) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.11. Entrada Therapeutics had a negative net margin of 2,895.05% and a negative return on equity of 51.22%. The firm had revenue of $0.88 million for the quarter, compared to analyst estimates of $2.92 million. Sell-side analysts expect that Entrada Therapeutics, Inc. will post -4.12 earnings per share for the current year.

Wall Street Analyst Weigh In

TRDA has been the topic of a number of research analyst reports. Guggenheim reduced their target price on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Monday, June 8th. HC Wainwright cut Entrada Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Roth Capital set a $10.00 price objective on Entrada Therapeutics in a research report on Friday, May 8th. Weiss Ratings lowered shares of Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. Finally, Oppenheimer upped their target price on shares of Entrada Therapeutics from $21.00 to $23.00 and gave the company an “outperform” rating in a research report on Monday, April 6th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Entrada Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $17.50.

Institutional Trading of Entrada Therapeutics

Several institutional investors have recently added to or reduced their stakes in TRDA. State of Wyoming lifted its stake in Entrada Therapeutics by 130.9% during the second quarter. State of Wyoming now owns 7,575 shares of the company’s stock worth $51,000 after purchasing an additional 4,295 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of Entrada Therapeutics by 72.7% in the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock valued at $51,000 after buying an additional 3,707 shares in the last quarter. Occudo Quantitative Strategies LP acquired a new stake in shares of Entrada Therapeutics in the second quarter valued at $68,000. IHT Wealth Management LLC purchased a new stake in shares of Entrada Therapeutics in the 2nd quarter valued at $72,000. Finally, Jain Global LLC purchased a new stake in shares of Entrada Therapeutics in the 3rd quarter valued at $69,000. Institutional investors and hedge funds own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.